Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Pardes Biosciences logo — On a mission to tackle pandemic-sized challenges with innova...

Pardes Biosciences

On a mission to tackle pandemic-sized challenges with innovative, oral antiviral treatments, paving the way for quicker patient recovery everywhere.

Founded 2020 Post-IPO Equity Total: $126.61M Biotechnology, Life Sciences

General Information

Company Name Pardes Biosciences
Founded Year 2020
Founders / Decision Makers
Team member Team member
Industries Biotechnology, Life Sciences
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with Pardes Biosciences. To contact Pardes Biosciences, visit pardesbio.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Pardes Biosciences compare?

A PDF of Pardes Biosciences and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Pardes Biosciences soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Pardes Biosciences

Pardes Biosciences is a clinical-stage biopharmaceutical company focused on addressing large-scale health crises, particularly targeting COVID-19. Utilizing modern reversible-covalent chemistry, the company is dedicated to discovering and developing innovative oral drug candidates to revolutionize patient access to treatments. Their primary product candidate, PBI-0451, is an oral antiviral drug aimed at treating and preventing SARS-CoV-2 infections. With a mission to halt pandemics and expedite patient recovery, Pardes Biosciences' efforts have garnered significant attention and support from the investor community. The company received a noteworthy $75.00M Post-IPO Equity investment on 27 December 2021, with leading investors including RA Capital Management, Frazier Healthcare Partners, T. Rowe Price, EcoR1 Capital, Foresite Capital, Gilead Sciences, Monashee Investment Management, and GMF CAPITAL. As the company continues to advance, their innovative approach and focus on pandemic-sized challenges position them as a significant player in the Biotechnology and Life Sciences industries.

Business keywords: biopharmaceutical company, clinical-stage, oral antiviral treatments, COVID-19, pandemic-sized challenges, SARS-CoV-2 infections, reversible-covalent chemistry, drug discovery, patient recovery, innovation in healthcare, pandemic solutions, pharmaceutical research, patient access, pandemic response, health crisis

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity $75.00M 8
RA Capital Management Frazier Healthcare Partners T. Rowe Price
RA Capital Management, Frazier Healthcare Partners +6
27 Dec 2021
Funding Round $51.61M 1
Y Combinator
Y Combinator
03 Feb 2021
Pre Seed Round Undisclosed 1
Olive Capital
Olive Capital
07 Sep 2020

Pardes Biosciences Alternatives & Competitors

Pardes Biosciences vs
Ordaos Bio
Ordaos Bio United States

Ordaōs creates de novo mini-proteins to help drug hunters deliver life-saving treatments.

Seed
24 employees
Biotechnology, Life Sciences

FAQ About Pardes Biosciences

On a mission to tackle pandemic-sized challenges with innovative, oral antiviral treatments, paving the way for quicker patient recovery everywhere.
Pardes Biosciences was founded in 2020.
Pardes Biosciences operates in Biotechnology and Life Sciences. Its work centres on biopharmaceutical company, clinical-stage, oral antiviral treatments and COVID-19.
Pardes Biosciences has completed 3 funding rounds, raising a total of $126.61M. The latest funding stage is Post-IPO Equity.
Top alternatives and competitors to Pardes Biosciences include Ordaos Bio. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Pardes Biosciences and Ordaos Bio are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Pardes Biosciences, https://bouncewatch.com/company/pardes-biosciences, updated 27 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes